Nevro Shares Rise 16% After 4Q, 2024 Revenue Guidance

Dow Jones

Jan 14, 2025

By Chris Wack

Nevro shares gained after the company said it expects to see fourth-quarter and full-year 2024 revenue higher than analysts' expectations.

The medical-device company's stock was up 16%, to $3.83, midday Monday.

Nevro said it expects to see quarterly earnings of $105 million to $106 million, compared with the $100.5 million analysts polled by FactSet are looking for.

For the full year, the company said it is looking for revenue of $408 million to $409 million, while analysts are forecasting revenue of $403.6 million.

Nevro said revenue is higher primarily due to the effect of greater-than-anticipated spinal cord stimulation device replacement procedures in the fourth quarter of 2024.

Cash, cash equivalents and short-term investments are expected to total $292.5 million as of Dec. 31, an increase of $15.5 million from Sept. 30.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

January 13, 2025 13:52 ET (18:52 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2503531286"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503531286\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2503531286?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-14 02:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503531286","market":"sg","top_or_hot":-1,"title":"Nevro Shares Rise 16% After 4Q, 2024 Revenue Guidance","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  Nevro shares gained after the company said it expects to see fourth-quarter and full-year 2024 revenue higher than analysts' expectations. \n</p>\n<p>\n  The medical-device company's stock was up 16%, to $3.83, midday Monday. \n</p>\n<p>\n  Nevro said it expects to see quarterly earnings of $105 million to $106 million, compared with the $100.5 million analysts polled by FactSet are looking for. \n</p>\n<p>\n  For the full year, the company said it is looking for revenue of $408 million to $409 million, while analysts are forecasting revenue of $403.6 million. \n</p>\n<p>\n  Nevro said revenue is higher primarily due to the effect of greater-than-anticipated spinal cord stimulation device replacement procedures in the fourth quarter of 2024. \n</p>\n<p>\n  Cash, cash equivalents and short-term investments are expected to total $292.5 million as of Dec. 31, an increase of $15.5 million from Sept. 30. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 13, 2025 13:52 ET (18:52 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nevro Shares Rise 16% After 4Q, 2024 Revenue Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNevro Shares Rise 16% After 4Q, 2024 Revenue Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-14 02:52</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  Nevro shares gained after the company said it expects to see fourth-quarter and full-year 2024 revenue higher than analysts' expectations. \n</p>\n<p>\n  The medical-device company's stock was up 16%, to $3.83, midday Monday. \n</p>\n<p>\n  Nevro said it expects to see quarterly earnings of $105 million to $106 million, compared with the $100.5 million analysts polled by FactSet are looking for. \n</p>\n<p>\n  For the full year, the company said it is looking for revenue of $408 million to $409 million, while analysts are forecasting revenue of $403.6 million. \n</p>\n<p>\n  Nevro said revenue is higher primarily due to the effect of greater-than-anticipated spinal cord stimulation device replacement procedures in the fourth quarter of 2024. \n</p>\n<p>\n  Cash, cash equivalents and short-term investments are expected to total $292.5 million as of Dec. 31, an increase of $15.5 million from Sept. 30. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 13, 2025 13:52 ET (18:52 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVRO","symbol_name":"Nevro Corp.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2503531286","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503531286","pubTimestamp":1736794320,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Nevro shares gained after the company said it expects to see fourth-quarter and full-year 2024 revenue higher than analysts' expectations.The medical-device company's stock was up 16%, to $3.83, midday Monday.Nevro said it expects to see quarterly earnings of $105 million to $106 million, compared with the $100.5 million analysts polled by FactSet are looking for.For the full year, the company said it is looking for revenue of $408 million to $409 million, while analysts are forecasting revenue of $403.6 million.Nevro said revenue is higher primarily due to the effect of greater-than-anticipated spinal cord stimulation device replacement procedures in the fourth quarter of 2024.Cash, cash equivalents and short-term investments are expected to total $292.5 million as of Dec. 31, an increase of $15.5 million from Sept. 30.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"NVRO":"Nevro Corp."},"translate_title":"2024年第四季度收入指引公布后，Nevro股价上涨16%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVRO":1},"content_text":"By Chris Wack \n\n\n \n\n\n  Nevro shares gained after the company said it expects to see fourth-quarter and full-year 2024 revenue higher than analysts' expectations. \n\n\n  The medical-device company's stock was up 16%, to $3.83, midday Monday. \n\n\n  Nevro said it expects to see quarterly earnings of $105 million to $106 million, compared with the $100.5 million analysts polled by FactSet are looking for. \n\n\n  For the full year, the company said it is looking for revenue of $408 million to $409 million, while analysts are forecasting revenue of $403.6 million. \n\n\n  Nevro said revenue is higher primarily due to the effect of greater-than-anticipated spinal cord stimulation device replacement procedures in the fourth quarter of 2024. \n\n\n  Cash, cash equivalents and short-term investments are expected to total $292.5 million as of Dec. 31, an increase of $15.5 million from Sept. 30. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 13, 2025 13:52 ET (18:52 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}